Article

What do we mean by normal-tension glaucoma?

Ophthalmologists do not agree on whether normal-tension glaucoma (NTG) is the same as primary-open angle glaucoma (POAG). Angelo P. Tanna, MD, director of the Glaucoma Service, Feinberg School of Medicine, Northwestern University, Chicago, approached this debate by offering a detailed definition of NTG.

Ophthalmologists do not agree on whether normal-tension glaucoma(NTG) is the same as primary-open angle glaucoma (POAG). AngeloP. Tanna, MD, director of the Glaucoma Service, Feinberg Schoolof Medicine, Northwestern University, Chicago, approached thisdebate by offering a detailed definition of NTG.

Glaucoma is a group of diseases with a shared final commonpathway of optic neuropathy characterized by progressive retinalganglion cell loss, optic disc excavation, and correspondingvision loss. According to Dr. Tanna, NTG is POAG that isaggressive in nature and occurs in the absence of a known historyof statistically abnormal IOP. In POAG, however, IOP is acontinuous risk factor for development of disease.

To describe NTG in terms of "normal" or "abnormal" IOP isawkward, because the generally accepted cut-off point of 21 mm Hgis an arbitrary limit based on the mean plus two standarddeviations found in large population studies, Dr. Tanna said.

As an example, he questioned the logic of classifying a patientwho develops glaucoma at an IOP of 20 mm Hg as having a differentdisease than someone who develops glaucoma with an IOP of 22 mmHg. Many individuals with IOP over 21 mm Hg do not developglaucomatous optic neuropathy, regardless of their cornealthickness, even when followed for a number of years.

The optic nerve changes in response to disease processes in alimited number of ways, such as excavation and swelling.

"It's naive to believe that only one mechanism can lead to opticdisc excavation," Dr. Tanna said. "More likely, many differentmolecular and cellular abnormalities conspire to result in whatwe call glaucomatous optic disc neuropathy. It's safe to assumethat at lower [IOPs], these pressure-independent types ofmechanisms tend to predominate, whereas at higher [IOPs],pressure-dependent mechanisms probably tend to predominate."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.